Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Salvage Therapy"" wg kryterium: Temat


Tytuł :
Outcome of Salvage Therapy in Isolated Regional Recurrence in Head and Neck Squamous Cell Carcinoma.
Autorzy :
Giger R; Department of Otorhinolaryngology-Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Fink R; Department of Otorhinolaryngology-Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Demattè M; Department of Otorhinolaryngology-Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department of Otorhinolaryngology-Head and Neck Surgery, Head and Neck and Sensory Organs Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Visini M; Department of Otorhinolaryngology-Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Elicin O; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Anschuetz L; Department of Otorhinolaryngology-Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Pokaż więcej
Źródło :
The Laryngoscope [Laryngoscope] 2021 Jan; Vol. 131 (1), pp. 67-72. Date of Electronic Publication: 2020 Feb 14.
Typ publikacji :
Journal Article
MeSH Terms :
Salvage Therapy*
Neoplasm Recurrence, Local/*therapy
Squamous Cell Carcinoma of Head and Neck/*therapy
Female ; Humans ; Male ; Middle Aged ; Neck Dissection ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy.
Autorzy :
Kanthabalan A; Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom.
Arya M; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom.
Freeman A; Department of Histopathology, UCLH NHS Foundation Trust, London, United Kingdom.
Mitra AV; Department of Clinical Oncology, UCLH NHS Foundation Trust, London, United Kingdom.
Payne H; Department of Clinical Oncology, UCLH NHS Foundation Trust, London, United Kingdom.
Peters M; Department of Radiation Oncology, University Medical Centre Utrecht, The Netherlands.
Shah TT; Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Imperial Urology, Imperial College Healthcare NHS Trust, London, United Kingdom.
Emberton M; Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom.
Ahmed HU; Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Imperial Urology, Imperial College Healthcare NHS Trust, London, United Kingdom.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2020 Nov; Vol. 204 (5), pp. 950-955. Date of Electronic Publication: 2020 Jun 30.
Typ publikacji :
Journal Article
MeSH Terms :
Ablation Techniques/*methods
Kallikreins/*blood
Neoplasm Recurrence, Local/*therapy
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*therapy
Salvage Therapy/*methods
Ablation Techniques/adverse effects ; Aged ; Humans ; Image-Guided Biopsy/methods ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/pathology ; Patient Selection ; Positron Emission Tomography Computed Tomography ; Prostate/diagnostic imaging ; Prostate/pathology ; Prostate/radiation effects ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/pathology ; Risk Assessment ; Salvage Therapy/adverse effects
Czasopismo naukowe
Tytuł :
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
Autorzy :
Zhao JY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, 030001, China.
Liu SN; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China.
Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Chen YH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Liu KY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China.; Peking-Tsinghua Center for Life Sciences, Beijing, 100044, China.
Mo XD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. .; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 169-180. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji :
Journal Article
MeSH Terms :
Cyclophosphamide*
Hematopoietic Stem Cell Transplantation*/trends
Salvage Therapy*/trends
Transplantation, Haploidentical*/trends
Drug Resistance, Multiple/*drug effects
Graft vs Host Disease/*drug therapy
Pyrazoles/*therapeutic use
Adolescent ; Adult ; Child ; Child, Preschool ; Drug Resistance, Multiple/physiology ; Female ; Follow-Up Studies ; Graft vs Host Disease/diagnosis ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Transplantation, Homologous/trends ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
Autorzy :
Candoni A; Clinica Ematologica Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
Lazzarotto D; Clinica Ematologica Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
Ferrara F; U.O.C. Ematologia, Naples, Italy.
Curti A; Dipartimento di Oncologia ed Ematologia, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Lussana F; U.O.C. Ematologia, Ospedale di Bergamo ASST Papa Giovanni XXIII, Bergamo, Italy.
Papayannidis C; Dipartimento di Oncologia ed Ematologia, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Del Principe MI; U.O.C. Ematologia, AOU Policlinico Tor Vergata, Rome, Italy.
Bonifacio M; Clinica Ematologica, Università di Verona, Verona, Italy.
Mosna F; Ematologia e Centro Trapianto di Midollo Osseo, Ospedale Regionale San Maurizio, Bolzano, Italy.
Delia M; U.O. Ematologia con Trapianto, Azienda Ospedaliero-Universitaria Consorziale, Bari, Italy.
Minetto P; Clinica Ematologica, Ospedale San Martino, Genoa, Italy.
Gottardi M; U.O.C. Ematologia, Ospedale di Treviso, Treviso, Italy.
Fracchiolla N; U.O. Ematologia, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Mancini V; Dipartimento di Ematologia e Oncologia, Ospedale Niguarda, Milan, Italy.
Forghieri F; S.C. Ematologia, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
Zappasodi P; Clinica Ematologica, IRCCS Policlinico San Matteo, Pavia, Italy.
Cerrano M; S.C. Ematologia 1, A.O.U. Citta della Salute e della Scienza di Torino (Presidio Molinette), Torino, Italy.
Vitale A; Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, 'Sapienza' Università di Roma, Rome, Italy.
Audisio E; S.C. Ematologia 2, Torino, Italy.
Trappolini S; S.O.D. Clinica Ematologica, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.
Romani C; U.O. Ematologia, Cagliari, Italy.
Defina M; UOC Ematologia, Azienda Ospedaliero Universitaria Senese, Siena, Italy.
Imbergamo S; U.O. di Ematologia e Immunologia Clinica, Università degli Studi di Padova, Padova, Italy.
Ciccone N; S.C. Ematologia, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy.
Santoro L; U.O.C. Ematologia e Trapianto di Midollo Osseo, Avellino, Italy.
Cambò B; UOC Ematologia e Centro Trapianti di Midollo Osseo, Azienda Ospedaliero Universitaria di Parma, Parma, Italy.
Iaccarino S; U.O.C. Ematologia, Azienda Ospedaliera di Caserta, Caserta, Italy.
Dargenio M; S.C. Ematologia, Ospedale Vito Fazzi, Lecce, Italy.
Aprile L; S.C. Ematologia, Ospedale S.G. Moscati, Taranto, Italy.
Chiaretti S; Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, 'Sapienza' Università di Roma, Rome, Italy.
Fanin R; Clinica Ematologica Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
Pizzolo G; Clinica Ematologica, Università di Verona, Verona, Italy.
Foà R; Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, 'Sapienza' Università di Roma, Rome, Italy.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1466-1472. Date of Electronic Publication: 2020 Aug 31.
Typ publikacji :
Clinical Trial, Phase IV; Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Salvage Therapy*
Nalbuphine/*administration & dosage
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adolescent ; Adult ; Allografts ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Nalbuphine/adverse effects ; Recurrence ; Survival Rate
Czasopismo naukowe
Tytuł :
Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study).
Autorzy :
Keino D; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Yokosuka T; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Hirose A; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Sakurai Y; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Nakamura W; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Fujita S; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Hayashi A; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Miyagawa N; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Iwasaki F; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Hamanoue S; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Yanagimachi M; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Shiomi M; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Goto S; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Kitagawa N; Division of Surgery, Kanagawa Children's Medical Center, Yokohama, Japan.
Tanaka M; Division of Diagnostic Pathology, Kanagawa Children's Medical Center, Yokohama, Japan.
Nozawa K; Division of Radiology, Kanagawa Children's Medical Center, Yokohama, Japan.
Tanaka Y; Division of Diagnostic Pathology, Kanagawa Children's Medical Center, Yokohama, Japan.
Goto H; Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Nov; Vol. 67 (11), pp. e28655. Date of Electronic Publication: 2020 Aug 15.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Carcinoma, Hepatocellular/pathology ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Infant ; Irinotecan/administration & dosage ; Liver Neoplasms/pathology ; Male ; Neoplasm Recurrence, Local/pathology ; Pilot Projects ; Prognosis ; Sorafenib/administration & dosage ; Survival Rate
Czasopismo naukowe
Tytuł :
Editorial Comment.
Autorzy :
Sanchez-Salas R; Department of Urology, L'Institut Mutualiste Montsouris, Université Paris Descartes, Paris, France.
Cathelineau X; Department of Urology, L'Institut Mutualiste Montsouris, Université Paris Descartes, Paris, France.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2020 Nov; Vol. 204 (5), pp. 954-955. Date of Electronic Publication: 2020 Sep 10.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Neoplasms*
Salvage Therapy*
Biopsy ; Humans ; Male ; Prostate ; Recurrence
Czasopismo naukowe
Tytuł :
Inguinal Lymph Node Dissection Does Not Improve Overall Survival in Anal Cancer Nodal Disease.
Autorzy :
Lin ACH; Department of Surgery, Cooper University Hospital, Camden, New Jersey.
Hakim A; School of Medicine, Cooper Medical School of Rowan University, Camden, New Jersey.
Kellish AS; School of Medicine, Cooper Medical School of Rowan University, Camden, New Jersey.
Singh P; School of Medicine, Cooper Medical School of Rowan University, Camden, New Jersey.
Wozniak M; School of Medicine, Cooper Medical School of Rowan University, Camden, New Jersey.
Kwiatt M; Department of Surgery, Cooper University Hospital, Camden, New Jersey.
Gaughan J; Department of Surgery, Cooper University Hospital, Camden, New Jersey.
Hong YK; Department of Surgery, Cooper University Hospital, Camden, New Jersey. Electronic address: .
Pokaż więcej
Źródło :
The Journal of surgical research [J Surg Res] 2020 Nov; Vol. 255, pp. 13-22. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article
MeSH Terms :
Anus Neoplasms/*therapy
Carcinoma, Squamous Cell/*therapy
Lymph Node Excision/*statistics & numerical data
Lymphatic Metastasis/*therapy
Proctectomy/*methods
Salvage Therapy/*statistics & numerical data
Aged ; Anus Neoplasms/mortality ; Anus Neoplasms/pathology ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/secondary ; Chemoradiotherapy, Adjuvant ; Female ; Humans ; Inguinal Canal ; Kaplan-Meier Estimate ; Lymph Nodes/pathology ; Lymph Nodes/surgery ; Male ; Middle Aged ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Patient Selection ; Proctectomy/statistics & numerical data ; Retrospective Studies ; Salvage Therapy/methods
Czasopismo naukowe
Tytuł :
A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
Autorzy :
Horisawa Y; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
Kondo T; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan. .
Hishizawa M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
Yamashita K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2699-2701. Date of Electronic Publication: 2020 Apr 21.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Bone Marrow Transplantation*
Molecular Targeted Therapy*
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Plasma Cell/*therapy
ADP-ribosyl Cyclase 1/antagonists & inhibitors ; ADP-ribosyl Cyclase 1/immunology ; Allografts ; Antibodies, Monoclonal/administration & dosage ; Antigens, Neoplasm/immunology ; Antineoplastic Agents, Immunological/administration & dosage ; Bortezomib/administration & dosage ; Combined Modality Therapy ; Dexamethasone/administration & dosage ; Humans ; Lenalidomide/administration & dosage ; Leukemia, Plasma Cell/drug therapy ; Male ; Membrane Glycoproteins/antagonists & inhibitors ; Membrane Glycoproteins/immunology ; Middle Aged ; Peripheral Blood Stem Cell Transplantation ; Remission Induction ; Transplantation Conditioning ; Transplantation, Autologous
Raport
Tytuł :
Ocular preservation in patients with bilateral retinoblastoma before chemotherapy in situ era: A report from a Mexican Retinoblastoma Reference Hospital.
Autorzy :
Del Carmen Bernal-Díaz Z; Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Murillo-Maldonado MA; Department of Oncology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Pérez-Villanueva H; Department of Radiation Oncology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Reyes-López A; Center for Economic Studies in Health, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Ramírez-Ortiz MA; Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Oct; Vol. 67 (10), pp. e28625. Date of Electronic Publication: 2020 Aug 03.
Typ publikacji :
Journal Article
MeSH Terms :
Salvage Therapy*
Eye/*drug effects
Eye/*radiation effects
Orbital Neoplasms/*therapy
Organ Sparing Treatments/*methods
Retinal Neoplasms/*therapy
Retinoblastoma/*therapy
Chemoradiotherapy/methods ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Infant ; Male ; Mexico ; Orbital Neoplasms/pathology ; Prognosis ; Retinal Neoplasms/pathology ; Retinoblastoma/pathology ; Visual Acuity
Czasopismo naukowe
Tytuł :
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Autorzy :
Solman IG; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, United States.
Blum LK; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, United States.
Hoh HY; Research, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, United States.
Kipps TJ; Department of Medicine, UCSD Moores Cancer Center, San Diego, CA, United States.
Burger JA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Barrientos JC; Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, United States.
O'Brien S; Department of Medicine, UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA, United States.
Mulligan SP; Department of Haematology, Royal North Shore Hospital, Sydney, Australia.
Kay NE; Division of Hematology, Department of Medicine, Mayo Clinic Cancer Center, Rochester, MN, United States.
Hillmen P; Department of Haematology, The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom.
Byrd JC; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Lal ID; Clinical Science, Pharmacyclics LLC, An AbbVie Company, Sunnyvale, CA, United States.
Dean JP; Clinical Science, Pharmacyclics LLC, An AbbVie Company, Sunnyvale, CA, United States.
Mongan A; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, United States. Electronic address: .
Pokaż więcej
Źródło :
Leukemia research [Leuk Res] 2020 Oct; Vol. 97, pp. 106432. Date of Electronic Publication: 2020 Aug 11.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell/*immunology
Neoplasm Recurrence, Local/*drug therapy
Neoplasm Recurrence, Local/*immunology
T-Lymphocytes, Regulatory/*immunology
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Case-Control Studies ; Chlorambucil/administration & dosage ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Middle Aged ; Natural Killer T-Cells/drug effects ; Natural Killer T-Cells/immunology ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Pyrazoles/administration & dosage ; Pyrimidines/administration & dosage ; T-Lymphocytes, Regulatory/drug effects
Czasopismo naukowe
Tytuł :
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Autorzy :
Pinczés LI; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.; Doctoral School of Clinical Medicine, University of Debrecen, Debrecen, Hungary.
Szabó R; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
Illés Á; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.; Doctoral School of Clinical Medicine, University of Debrecen, Debrecen, Hungary.
Földeák D; Division of Hematology, 2nd Department of Internal Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Piukovics K; Division of Hematology, 2nd Department of Internal Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Szomor Á; Division of Hematology, 1st Department of Internal Medicine, Faculty of Medicine, University of Pécs, Pecs, Hungary.
Gopcsa L; Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Miltényi Z; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary. .; Doctoral School of Clinical Medicine, University of Debrecen, Debrecen, Hungary. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Oct; Vol. 99 (10), pp. 2385-2392. Date of Electronic Publication: 2020 Aug 03.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hodgkin Disease/*drug therapy
Adolescent ; Adult ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/adverse effects ; Brentuximab Vedotin/administration & dosage ; Brentuximab Vedotin/adverse effects ; Combined Modality Therapy ; Drug Evaluation ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Hodgkin Disease/diagnostic imaging ; Hodgkin Disease/therapy ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multicenter Studies as Topic/statistics & numerical data ; Neutropenia/chemically induced ; Peripheral Nervous System Diseases/chemically induced ; Positron-Emission Tomography ; Progression-Free Survival ; Retrospective Studies ; Transplantation, Autologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Autorzy :
Kneebone A; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia. Electronic address: .
Fraser-Browne C; Auckland Hospital, Auckland, New Zealand.
Duchesne GM; University of Melbourne, Melbourne, VIC, Australia; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Fisher R; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Frydenberg M; Monash University, Melbourne, VIC, Australia; Cabrini Medical Centre, Melbourne, VIC, Australia.
Herschtal A; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Williams SG; University of Melbourne, Melbourne, VIC, Australia; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Brown C; National Health and Medical Research Council, Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Delprado W; Douglass Hanly Moir Pathology, Sydney, NSW, Australia; University of Notre Dame Australia, Sydney, NSW, Australia; Macquarie University, Sydney, NSW, Australia.
Haworth A; School of Physics, University of Sydney, Sydney, NSW, Australia.
Joseph DJ; University of Western Australia, Perth, WA, Australia; Edith Cowan University, Perth, WA, Australia; Genesis Cancer Care, Perth, WA, Australia; 5D Clinics, Perth, WA, Australia.
Martin JM; Calvary Mater Newcastle Hospital, Newcastle, NSW, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Matthews JHL; Auckland Hospital, Auckland, New Zealand.
Millar JL; Monash University, Melbourne, VIC, Australia; Alfred Health Radiation Oncology, Melbourne, VIC, Australia.
Sidhom M; Cancer Therapy Centre, Liverpool Hospital, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia.
Spry N; Edith Cowan University, Perth, WA, Australia; Sir Charles Gairdner Hospital, Perth, WA, Australia; Genesis Cancer Care, Perth, WA, Australia.
Tang CI; Edith Cowan University, Perth, WA, Australia; Sir Charles Gairdner Hospital, Perth, WA, Australia.
Turner S; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Crown Princess Mary Cancer Centre, Westmead, NSW, Australia.
Wiltshire KL; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Woo HH; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Department of Urology, Sydney Adventist Hospital, Wahroonga, NSW Australia.
Davis ID; Monash University, Melbourne, VIC, Australia; ANZUP Cancer Trials Group, Sydney, NSW, Australia; Eastern Health, Melbourne, VIC, Australia.
Lim TS; Genesis Cancer Care, Perth, WA, Australia; Curtin Medical School, Curtin University, Perth, WA, Australia.
Pearse M; Auckland Hospital, Auckland, New Zealand.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1331-1340.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Prostatectomy*
Salvage Therapy*/adverse effects
Adenocarcinoma/*radiotherapy
Prostatic Neoplasms/*radiotherapy
Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Adult ; Aged ; Australia ; Disease Progression ; Disease-Free Survival ; Dose Fractionation, Radiation ; Humans ; Male ; Male Urogenital Diseases/epidemiology ; Male Urogenital Diseases/etiology ; Middle Aged ; New Zealand ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/surgery ; Radiotherapy, Adjuvant/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Autorzy :
Sargos P; Institut Bergonié, Bordeaux, France. Electronic address: .
Chabaud S; Centre Léon Bérard, Lyon, France.
Latorzeff I; Clinique Pasteur, Toulouse, France.
Magné N; Institut de Cancérologie de la Loire, Saint-Priest-en-Jarèz, France.
Benyoucef A; Centre Henri Becquerel, Rouen, France.
Supiot S; Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain, France.
Pasquier D; Centre Oscar Lambret and Lille University, Lille, France.
Abdiche MS; Centre Hospitalier Robert Boulin, Libourne, France.
Gilliot O; Clinique Marzet, Pau, France.
Graff-Cailleaud P; Institut Claudius Regaud, Toulouse, France.
Silva M; Centre François Baclesse, Caen, France.
Bergerot P; Clinique Mutualiste de l'Estuaire, Cité Sanitaire, Saint-Nazaire, France.
Baumann P; Centre d'Oncologie de Gentilly, Nancy, France.
Belkacemi Y; Hôpitaux Universitaires Henri Mondor, Université Paris Est Créteil, Creteil, France.
Azria D; Institut Régional du Cancer de Montpellier Val d'Aurelle, Montpellier, France.
Brihoum M; Unicancer, Paris, France.
Soulié M; CHU de Toulouse, Toulouse, France.
Richaud P; Institut Bergonié, Bordeaux, France.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1341-1352.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Prostatectomy*
Salvage Therapy*/adverse effects
Adenocarcinoma/*radiotherapy
Androgen Antagonists/*administration & dosage
Prostatic Neoplasms/*radiotherapy
Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Aged ; Disease Progression ; France ; Humans ; Male ; Male Urogenital Diseases/epidemiology ; Male Urogenital Diseases/etiology ; Medical Overuse/prevention & control ; Middle Aged ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/surgery ; Radiotherapy, Adjuvant/adverse effects ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome.
Autorzy :
Adam EH; Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe-University, Frankfurt/Main, Germany. .
Schmid B; Department of Anaesthesiology and Critical Care, University Hospital Wuerzburg, Julius-Maximilians-University, Wuerzburg, Germany.
Sonntagbauer M; Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe-University, Frankfurt/Main, Germany.
Kranke P; Department of Anaesthesiology and Critical Care, University Hospital Wuerzburg, Julius-Maximilians-University, Wuerzburg, Germany.
Zacharowski K; Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe-University, Frankfurt/Main, Germany.
Meybohm P; Department of Anaesthesiology and Critical Care, University Hospital Wuerzburg, Julius-Maximilians-University, Wuerzburg, Germany.
Pokaż więcej
Źródło :
Critical care (London, England) [Crit Care] 2020 Sep 24; Vol. 24 (1), pp. 574. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Salvage Therapy*
Coronavirus Infections/*therapy
Critical Illness/*therapy
Fibrin Fibrinogen Degradation Products/*therapeutic use
Peptide Fragments/*therapeutic use
Pneumonia, Viral/*therapy
Respiratory Distress Syndrome/*therapy
Aged ; Betacoronavirus ; COVID-19 ; Comorbidity ; Female ; Humans ; Male ; Middle Aged ; Pandemics ; Respiratory Distress Syndrome/virology ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences.
Autorzy :
Hwang L; From the Department of Radiation Oncology.
Paluch J; Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA.
Jadvar H; Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA.
England JR; Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA.
Desai B; Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA.
Ballas LK; From the Department of Radiation Oncology.
Pokaż więcej
Źródło :
Clinical nuclear medicine [Clin Nucl Med] 2020 Sep; Vol. 45 (9), pp. 668-671.
Typ publikacji :
Journal Article
MeSH Terms :
Carboxylic Acids*
Cyclobutanes*
Salvage Therapy*
Prostatic Neoplasms/*diagnostic imaging
Prostatic Neoplasms/*therapy
Aged ; Androgen Antagonists/therapeutic use ; Bone Neoplasms/secondary ; Humans ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography ; Prostatic Neoplasms/pathology ; Recurrence
Czasopismo naukowe
Tytuł :
Early Discontinuation of Breast Free Flap Monitoring: A Strategy Driven by National Data.
Autorzy :
Baltodano PA; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Schalet G; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Rezak K; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Aliu O; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Weinberg M; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Ata A; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Agag RL; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Patel A; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Ricci JA; From the Division of Plastic Surgery, Department of Surgery, Albany Medical Center; the Division of Plastic, Maxillofacial, and Oral Surgery, Duke University School of Medicine; the Department of Plastic and Reconstructive Surgery, The Johns Hopkins University; and the Division of Plastic Surgery, Rutgers Robert Wood Johnson Medical Group.
Pokaż więcej
Źródło :
Plastic and reconstructive surgery [Plast Reconstr Surg] 2020 Sep; Vol. 146 (3), pp. 258e-264e.
Typ publikacji :
Journal Article
MeSH Terms :
Free Tissue Flaps*
Reoperation*
Salvage Therapy*
Mammaplasty/*methods
Postoperative Complications/*therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Humans ; Middle Aged ; Monitoring, Physiologic ; Risk Factors ; Time Factors ; United States ; Young Adult
Czasopismo naukowe
Tytuł :
Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies.
Autorzy :
El Kababri M; Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.; Metronomics Global Health Initiative, Rabat, Morocco.
Benmiloud S; Paediatric Haematology and Oncology Unit, Hospital Hassan II, Fes, Morocco.
Cherkaoui S; Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco.
El Houdzi J; Pediatic Haematology and Oncology Unit, Hospital Mohamed VI, Marrakech, Morocco.
Maani K; Paediatric Haematology and Oncology Unit, Hospital Ibn Rochd, Casablanca, Morocco.
Ansari N; Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.
Khoubila N; Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco.
Kili A; Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.
El Khorassani M; Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.
Madani A; Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco.
Tazi MA; National School of Public Health, Rabat, Morocco.
Ahid S; Pharmacoeconomics and Pharmacoepidemiology Research Team, Mohammed V University, Rabat, Morocco.; Laboratory of Biostatistics, Clinical and Epidemiological Research, Mohammed V University, Rabat, Morocco.
Hessissen L; Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.; Metronomics Global Health Initiative, Rabat, Morocco.
Quessar A; Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco.
Harif M; Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco.
Khattab M; Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.
André N; Paediatric Haematology and Oncology Department, La Timone Children's Hospital, Assistance Publique Hopitaux de Marseille, Marseille, France.; SMARTc Unit, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix Marseille Univ, Marseille, France.; Metronomics Global Health Initiative, Marseille, France.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Sep; Vol. 67 (9), pp. e28508. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Drug Resistance, Neoplasm/*drug effects
Neoplasm Recurrence, Local/*drug therapy
Neoplasms/*drug therapy
Adolescent ; Child ; Child, Preschool ; Cyclophosphamide/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Neoplasm Recurrence, Local/pathology ; Neoplasms/pathology ; Prognosis ; Survival Rate ; Valproic Acid/administration & dosage
Czasopismo naukowe
Tytuł :
The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
Autorzy :
Byrne M; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Danielson N; Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
Sengsayadeth S; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
Rasche A; Department of Nursing, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Culos K; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gatwood K; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Wyatt H; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Chinratanalab W; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
Dholaria B; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Ferrell PB; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Fogo K; Department of Nursing, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Goodman S; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
Jagasia M; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Jayani R; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Kassim A; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Mohan SR; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Savani BN; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Strickland SA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Engelhardt BG; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Savona M; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Sep; Vol. 95 (9), pp. 1006-1014. Date of Electronic Publication: 2020 Jun 15.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/mortality
Leukemia, Myeloid, Acute*/therapy
Salvage Therapy*
Bridged Bicyclo Compounds, Heterocyclic/*administration & dosage
Sulfonamides/*administration & dosage
Adult ; Aged ; Allografts ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Survival Rate
Czasopismo naukowe
Tytuł :
Primary Laryngectomy Versus Salvage Laryngectomy: A Comparison of Outcomes in the Chemoradiation Era.
Autorzy :
Sullivan CB; Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Ostedgaard KL; Department of Otolaryngology-Head and Neck Surgery, University of California at Davis, Sacramento, California.
Al-Qurayshi Z; Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Pagedar NA; Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Sperry SM; Department of Otolaryngology-Head and Neck Surgery, Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, U.S.A.
Pokaż więcej
Źródło :
The Laryngoscope [Laryngoscope] 2020 Sep; Vol. 130 (9), pp. 2179-2185. Date of Electronic Publication: 2019 Oct 25.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Carcinoma, Squamous Cell/*surgery
Laryngeal Neoplasms/*surgery
Laryngectomy/*methods
Postoperative Complications/*etiology
Salvage Therapy/*methods
Aged ; Carcinoma, Squamous Cell/mortality ; Chemoradiotherapy/methods ; Chemoradiotherapy/mortality ; Deglutition ; Female ; Humans ; Laryngeal Neoplasms/mortality ; Laryngectomy/mortality ; Male ; Middle Aged ; Postoperative Complications/mortality ; Prevalence ; Proportional Hazards Models ; Retrospective Studies ; Salvage Therapy/mortality ; Speech Therapy ; Speech, Alaryngeal ; Survival Rate ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies